Home About Us Members Register Brochure Contact Us Events Calendar Chinese WCC2008 WCC2009 WCC2010  
 

 Introduction to WCC
Cancer is a major killer in the world. BIT hopes to bring together anti-cancer experts from all over the world to advance cancer research and therapy through this unique meeting platform. Also, we aim to set up an important international communication platform for government organizations, universities, institutes, and enterprises to push forward the development of medicine and biotechnology in China and beyond. We strive to provide a high quality program designed to attract delegates from all cancer research disciplines including anti-cancer medicine development, and to encourage these researchers to interact and forge new collaborations.

 Event Report

BIT’s 4th World Congress of Cancer (WCC-2011), successfully held in Dalian World Expo Center on May 22-25, 2011. Totally, there were nearly 400 participants from more than 36 countries and areas have attended the WCC-2011.

As the keynote speakers, Dr. Michael Sela, Institute Professor of Immunology, Past President, Weizmann Institute of Science, Isreal; Christopher Ung, Vice President, Strategic Business & Operations, Oncology, Quintiles Medical Development Co., Ltd. USA; Paul W.H.I. Parren, Scientific Director & Senior Vice President, Genmab, The Netherlands and Xin-Yuan Liu, Member of Chinese Academy of Sciences, Institute of Biochemistry and Cell Biology, Professor, College of Life Science, Zhejiang Sci-Tech University, China made excellent presentations and warmly discussed with the audiences at keynote forum.

Initiated in 2008, wcc never stops her momentum to accelerating the cancer research and therapy. The informative program this year offered profound knowledge in current progress of medical research, innovation technologies, pathogenesis, diagnostics, prevention, treatment and clinical research of all various kinds of cancer. During conference, the participants enjoyed the new ideas, new finding, and new approaches from scientific and clinical leaders, renowned researchers worldwide. Simultaneously, we also provided opportunities for young scientists and newcomers in order to lead lively and interactive debates.

We would like to extend our thanks to all the participants and contributors to this conference. It is due to your keen interest that this field is expanding and exploring new frontiers.

Depending on the warmly support and good suggestions from all of the participants, we are confident in organizing wcc-2012 which would be better and more successful than wcc-2011.


 Opening Ceremony

 Keynote Speakers

Dr. Michael Sela, Institute Professor of Immunology, Past President, Weizmann Institute of Science, Isreal

Dr. Christopher Ung, Vice President, Strategic Business & Operations, Oncology, Quintiles Medical Development Co., Ltd. USA

Dr. Xin-Yuan Liu, Member of Chinese Academy of Sciences, Institute of Biochemistry and Cell Biology, Professor, College of Life Science, Zhejiang Sci-Tech University, China

Dr. Paul W.H.I. Parren,
Scientific Director & Senior Vice President, Genmab, The Netherlands
       

 Renowned Speakers
Dr. Henry Rodriguez, Director, Office of Cancer Clinical Proteomics Research, National Cancer Institute, USA Dr. Elio Riboli, Director, School of Public Health, Faculty of Medicine, Imperial College London, UK Dr. Michail Sitkovsky,
Director, Cancer Vaccine Center, Northeastern University, USA
Dr. Jim Mulshine, Vice President, Research, Rush University Medical Center, USA Dr. Rajesh C. Shrotriya,
CEO, Spectrum Pharmaceuticals, Inc., Canada
Dr. Kimlin Ashing-Giwa, Founding Director, CCARE, City of Hope National Medical Center, USA
Dr. Douglas Van Nostrand,
Director, Nuclear Medicine, Washington Hospital Center, USA
Dr. Anthony Goldstone, Professor, Director of Clinical Services, UCLH, UK Dr. Peter P. Chou, Director of Scientific Affair, Quest Diagnostics Nichols Institute, USA
Dr. Moshe Szyf, Director, Department of Pharmacology and Therapeutics, McGill University, Canada Dr. G. David Roodman, Vice Chair for Research, University of Pittsburgh School of Medicine, USA Dr. Ellen T Matloff, Director of the Cancer Genetic Counseling Program, Yale Cancer Center, USA
Dr. Bjoern Cochlovius,
Director Business Development, Pharmapartnering Oncology at Roche, Switzerland
Dr. Dongfeng Tan,
Professor, M.D. Anderson Cancer Center, USA
Dr. Susan E Langmore, Director, Boston Medical Center Speech & Hearing Sciences, Boston University, USA
Dr. Guan Chen, Professor, Medical College of Wisconsin, USA Dr. Charles N. Ellis, Director, University of Michigan Medical Center, USA Dr. Mariusz A. Wasik,
Director of Hematopathology, University of Pennsylvania, USA
Dr. Howard A. Reber, Distinguished Professor, Director, UCLA Center for Pancreatic Diseases, USA Dr. Christine McLaren,
Vice Chair, Department of Epidemiology, University of California, USA
Dr. Joan Guitart, Director, Cutaneous Lymphoma, Northwestern University, USA
Dr. Filippo G. Giancotti,
Professor, Memorial Sloan-Kettering Cancer Center; Professor, Cornell University, USA

Dr. Xinhua Ji,
Senior Investigator, Chief,
Biomolecular Structure Section, NCI, USA

Dr. Jose G. Guillem,
Vice President, Memorial Sloan-Kettering Cancer Center, USA
Dr. Maureen Simmonds, Head, School of Physiotherapy, Curtin University of Technology, Australia Dr. Rino Cerio, Director CMS/CAU, Cutaneous Medicine and Surgery, The Royal London Hospital, UK Dr.  Hope S. Rugo, Director, UCSF Helen Diller Family Comprehensive Cancer Center, USA
Dr. Saeed R Khan, Director, Medicinal Chemistry Core Sidney Kimmel Comprehensive Cancer Center, USA Dr. Barrie R. Cassileth,
Chief, Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, USA
Dr. Stephen C. Yang,
Director, Surgery Clerkship and Curriculum, The Johns Hopkins Medical Institutions, USA

 Programmed Tracks at a Glance

Track 1:
Medical Research on Major Cancers

Track 6:
Lung Cancer

Track 2:
Basic Sciences in Cancer Research

Track 7:
Cancer Nursing, Support Care and Public Health

Track 3:
Innovation Technologies
in Cancer Research

Track 8:
Cancer Prevention
and Complimentary Therapy

Track 4:
Anti-Cancer Drug Discovery
and Development

Track 9:
Session for Young Scientists

Track 5:
Cancer Diagnostics, Therapy and Clinical Update

 

  Background of WCC

  BIT's 3rd Annual World Cancer Congress (WCC-2010) was successfully held during June 22-25, 2010 in EXPO, Singapore. Dr. Dave S. B. Hoon, Director, Department of Molecular Oncology, John Wayne Cancer Institute, USA; Dr. Hartmuth C. Kolb, Vice President, Siemens Medical Solutions, USA, Molecular Imaging, USA; Dr. Mansoor Mohammed, President and CEO, ComniMatrix Diagnostics, USA gave keynote speeches. Altogether more than 800 participants joined WCC-2010
                                         …… More


   Scenery of Dalian
Dalian Bin Yu Valley Dalian Forest Zoo Dalian Shell Plaza
Dalian Sun Asia Ocean World Dalian Tiger Beach Dalian Xinghai Square
Hosting Organizations

News Release

  • Early bird registration is available before April 30, 2011

  • Abstracts submission is open

  • Calling for new session proposals

  • Calling for collaborative organizations

  • Young Scientist Forum is open


Hosting Organizations
Information Research Center of International Talent, SAFEA
China Medicinal Biotech Association

Operating Organization

BIT Congress, Inc.

 
Foreign Experts Databank
of SAFEA-Dalian Biotechnological and Medical Experts Subdivision

Support Organizations

China Council for the Promotion of
International Trade
Dalian Sub-Council
-----------------------------------------
Nature Review

Media Partners

Conferences & Trade Shows
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

© 2008-2011 All right reserved for BIT World Congress (Dalian) Inc. Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897